Tolerability and Efficacy of Almotriptan in the Long-Term Treatment of Migraine

Pascual, Julio; Falk, R.; Docekal, R.; Prusínski, A; Jelencsik, J.; Cabarrocas, Xavier; Segarra, X.; Luria, X; Ferrer, P.

doi:10.1159/000052131

Cited by 46 publications

(49 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results from long-term open-label studies of almotriptan are available from two trials, a 6-month trial that enrolled 611 patients and a 12-month trial that enrolled 805 patients [11,12] . Both trials collected data from an average of 18 attacks per patient.…”

Section: Long-term Open-label Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Tolerability of Almotriptan in Controlled Clinical Trials

Mathew¹

2005

Eur Neurol

View full text Add to dashboard Cite

Seven triptans are now available for the acute treatment of migraine. While all of these agents have been shown to be safe and more or less well tolerated, they differ in ways that are clinically relevant to individual patients. Almotriptan has been investigated in approximately 3,500 patients enrolled in short-term clinical trials and 1,500 patients enrolled in long-term open-label trials. In a meta-analysis of placebo-controlled almotriptan trials (n = 2,294), treatment with almotriptan 12.5 mg results in a 2-hour pain-relief rate of 63.7% and a 2-hour pain-free rate of 36.4%. Almotriptan is associated with a rapid onset of action, with 30-min pain-relief and pain-free rates significantly better than placebo (p < 0.05). Direct comparator studies show the efficacy of almotriptan 12.5 mg to be comparable to that of sumatriptan but almotriptan is associated with superior tolerability. Trials assessing the efficacy of almotriptan over multiple attacks show that this agent is associated with a consistent and persistent response, not differing from the first to the last attack, an important property for a medication used to treat a chronic condition such as migraine. Early intervention with almotriptan enhances the activity of this agent. Treatment of mild pain with almotriptan has resulted in 2-hour pain-free rates of 84 and 77% and a sustained pain-free rate of 67%. Early treatment (within 1 h) of moderate to severe headaches with almotriptan also improves outcomes. In conclusion, clinical trials and post hoc analyses of such trials have shown almotriptan to be effective and well tolerated for the acute treatment of migraine. Its placebo-like tolerability makes it a good choice for early intervention, a strategy associated with better patient outcomes.

show abstract

Section: Long-term Open-label Clinical Trialsmentioning

confidence: 99%

“…Consistency of response was assessed in the 12-month open-label study [12] . Two-hour pain relief was obtained by 61.8% of patients for 6 80% of their attacks during the trial, by 77.7% of patients for 6 60% of their attacks, and 86.7% of patients for 6 40% of their attacks.…”

Section: Long-term Open-label Clinical Trialsmentioning

confidence: 99%

Efficacy and Tolerability of Almotriptan in Controlled Clinical Trials

Mathew¹

2005

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…A total of 51% of patients experienced adverse events, 29% of these being considered almotriptan-related, most being mild and transient. No relevant abnormalities in ECG or laboratory parameters were found at follow-up 5 .…”

Section: Safety and Tolerabilitymentioning

confidence: 82%

Almotriptan: Pharmacological Differences and Clinical Results

Pascual

2001

Current Medical Research and Opinion

View full text Add to dashboard Cite

In this manuscript we review the key basic and clinical data of almotriptan, the new selective 5-HT(1B/D) agonist developed for the symptomatc treatment of migraine. Among triptans, almotriptan has the highest oral bioavailability, with more than two-thirds of the administered dose absorbed within the first hourboth inside and outside a migraine attack. Gender or the presence of food in the stomach do not influence this pharmacokinetic profile, and its clean metabolism results in no relevant interactions with other medications. The dose exhibiting the best efficacy/ tolerability ratio is 12.5 mg. Efficacy parameters with this dose are very comparable to those of sumatriptan 100 mg, with a recurrence rate in the lower range. The tolerability of almotriptan is similar to that for placebo. The incidence of chest symptoms is very low (<1%), even though this drug remains contraindicated in patients with ischaemic cardiomyopathy. In summary, almotriptan's promising basic profile together with its excellent tolerability/safety profile and good efficacy confirm this new 5-HT(1B/D) agonist as a drug of choice for the symptomatic treatment of migraine attacks.

show abstract

“…Almotriptan was well-tolerated and no serious treatmentrelated adverse events or deaths occurred during the course of this study. The most commonly-reported adverse events were somnolence (1.8%), fatigue (1.7%) and vomiting (1.7%) [39]. In the 1-year European study, almotriptan 12.5 mg was effective in treating a total of 13,751 attacks of any intensity in 762 patients.…”

Section: Long-term Open-label Studiesmentioning

confidence: 99%

“…The long-term efficacy and tolerability of oral almotriptan in the treatment of migraine has been demonstrated in two open-label trials of 6 and 12 months duration [38,39]. In the 6month US study of 582 patients, 76% of patients reported headache relief, while 49% were pain free at 2 h following oral almotriptan 12.5 mg administered at the onset of the attack [38].…”

Section: Long-term Open-label Studiesmentioning

confidence: 99%

Oral almotriptan: practical uses in the acute treatment of migraine

Dowson¹

2004

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Almotriptan (Almogran, Lundbeck; Almirall Prodesfarma; Axert, Ortho-McNeil) is a novel 5-HT(1B/1D) receptor agonist (triptan) that is widely available on prescription for the acute treatment of migraine. Almotriptan has pharmacodynamic and pharmacokinetic profiles that make it suitable for use in this indication. It is a potent agonist at 5-HT(1B), (1D) and (1F) receptors, while having a low affinity for other 5-HT receptors. It is also a potent inhibitor of neurogenic inflammation. Almotriptan has a high oral bioavailability, is absorbed rapidly, has a relatively short plasma half-life and its route of elimination presents few potential problems. Placebo-controlled dose-finding studies have demonstrated that almotriptan tablets are effective and well-tolerated in the acute treatment of migraine, with a 12.5 mg dose providing the best balance between efficacy and tolerability. Large placebo-controlled studies show that the efficacy of oral almotriptan is comparable with that of the other oral triptans. In direct comparator-controlled studies, almotriptan was as effective as sumatriptan 50 and 100 mg but had a superior tolerability profile. Furthermore, the efficacy and tolerability of almotriptan is sustained in the long term following open-label administration. Meta-analyses and post hoc analyses of clinical data confirm these findings. In conclusion, almotriptan 12.5 mg is a good therapeutic choice for the symptomatic treatment of acute migraine attacks.

show abstract

Tolerability and Efficacy of Almotriptan in the Long-Term Treatment of Migraine

Cited by 46 publications

References 17 publications

Efficacy and Tolerability of Almotriptan in Controlled Clinical Trials

Efficacy and Tolerability of Almotriptan in Controlled Clinical Trials

Almotriptan: Pharmacological Differences and Clinical Results

Oral almotriptan: practical uses in the acute treatment of migraine

Contact Info

Product

Resources

About